nextech labs retatrutide GLP-3 (Reta) 20mg Retatrutide 10mg (GLP-3 RT) –

5ac), and liver triacylglycerol (TG) content (Figs

Molecular Identity Developer Innovent Biologics (China) / Eli Lilly partnership Mechanism Dual GLP-1 and glucagon receptor agonist GIP Activation No Administration Weekly subcutaneous Development Stage Phase 3 trials (primarily in China) Glucagon Receptor Pathway The glucagon receptor activation in Mazdutide engages metabolic pathways distinct from GIP: Hepatic metabolism: Glucagon signaling activates liver-based energy expenditure pathways Thermogenesis: Documented effects on energy expenditure in preclinical models Lipid metabolism: Research indicates effects on liver lipid processing Different satiety mechanism: Complementary to GLP-1's central appetite effects Published Research Mazdutide clinical data has been published primarily from Chinese trial populations: Trial Phase Population Key Findings GLORY-1 Phase 3 Chinese adults Metabolic endpoints documented GLORY-2 Phase 3 Chinese adults Glycemic pathway effects documented IBI362 Phase 2 Phase 2 Multiple cohorts Dose-response relationships established Tirzepatide: GLP-1 + GIP Tirzepatide represents the most established dual-agonist compound with full FDA approval and extensive published literature

Heres a summary of non-injection options: Rybelsus This is the only widely available oral GLP-1 medication

I have a ton of muscle on me

Bariatric surgery affects the glucoregulatory function of multiple target organs, including the intestine, liver, pancreas, adipose tissue and skeletal muscle

What Retatrutide Is and Where It Stands in Development Retatrutide is an experimental triple receptor agonist that activates the GLP-1, GIP, and glucagon receptors simultaneously